Patents by Inventor Aaron Avivi

Aaron Avivi has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • fibroblast-derived anti-cancer agents
    Patent number: 11628187
    Abstract: A conditioned cell culture medium of cells derived from Spalax or naked mole rat (Heterocephalus glaber) and methods for preparing it are provided. Pharmaceutical compositions comprising the conditioned cell culture medium and its use in the treatment of cancer as well as methods for identifying anti-cancer agents are also provided.
    Type: Grant
    Filed: November 20, 2017
    Date of Patent: April 18, 2023
    Assignee: CARMEL-HAIFA UNIVERSITY ECONOMIC CORP. LTD.
    Inventors: Aaron Avivi, Imad Shams, Irena Manov
  • SPALAX FIBROBLAST-DERIVED ANTI-CANCER AGENTS
    Publication number: 20220079992
    Abstract: A conditioned cell culture medium of cells derived from Spalax or naked mole rat (Heterocephalus glaber) and methods for preparing it are provided. Pharmaceutical compositions comprising the conditioned cell culture medium and its use in the treatment of cancer as well as methods for identifying anti-cancer agents are also provided.
    Type: Application
    Filed: November 19, 2021
    Publication date: March 17, 2022
    Inventors: Aaron Avivi, Imad Shams, Irena Manov
  • SPALAX FIBROBLAST-DERIVED ANTI-CANCER AGENTS
    Publication number: 20180200304
    Abstract: A conditioned cell culture medium of cells derived from Spalax or naked mole rat (Heterocephalus glaber) and methods for preparing it are provided. Pharmaceutical compositions comprising the conditioned cell culture medium and its use in the treatment of cancer as well as methods for identifying anti-cancer agents are also provided.
    Type: Application
    Filed: November 20, 2017
    Publication date: July 19, 2018
    Inventors: Aaron Avivi, Imad Shams, Irena Manov
  • SPALAX FIBROBLAST-DERIVED ANTI-CANCER AGENTS
    Publication number: 20140248371
    Abstract: A conditioned cell culture medium of cells derived from Spalax or naked mole rat (Heterocephalus glaber) and methods for preparing it are provided. Pharmaceutical compositions comprising the conditioned cell culture medium and its use in the treatment of cancer as well as methods for identifying anti-cancer agents are also provided.
    Type: Application
    Filed: January 9, 2014
    Publication date: September 4, 2014
    Applicant: CARMEL-HAIFA UNIVERSITY ECONOMIC CORP. LTD.
    Inventors: Aaron Avivi, Imad Shams, Irena Manov
  • Heparanases and splice variants thereof, polynucleotides encoding them and uses thereof
    Patent number: 8093031
    Abstract: The invention relates to novel heparanases, heparanase splice variants, and to polynucleotides encoding them. Particularly, the invention relates to Spalax heparanases, and to Spalax and human heparanase splice variants. Heparanase splice variants can be used, for example, to modulate the activity of heparanase in diseases disorders or conditions caused by or associated with the enzymatic activity of heparanase. For instance, a splice variant capable of down regulating the activity of heparanase can be used to treat primary tumors and/or to prevent or treat metastasis.
    Type: Grant
    Filed: September 20, 2006
    Date of Patent: January 10, 2012
    Assignee: Carmel-Haifa University Economic Corp. Ltd.
    Inventors: Nicola J. Nasser, Aaron Avivi, Israel Vlodavsky, Eviatar Nevo
  • Heparanases and Splice Variants Thereof, Ponucleotides Encoding Them and Uses Thereof
    Publication number: 20080248020
    Abstract: The invention relates to novel heparanases, heparanase splice variants, and to polynucleotides encoding them. Particularly, the invention relates to Spalax heparanases, and to Spalax and human heparanase splice variants. Heparanase splice variants can be used, for example, to modulate the activity of heparanase in diseases disorders or conditions caused by or associated with the enzymatic activity of heparanase. For instance, a splice variant capable of down regulating the activity of heparanase can be used to treat primary tumors and/or to prevent or treat metastasis.
    Type: Application
    Filed: September 20, 2006
    Publication date: October 9, 2008
    Applicant: RAPPAPORT FAMILY INSTITUTE FOR RESEARCH IN THE MEDICAL SCIENCES
    Inventors: Nicola J. Nasser, Aaron Avivi, Israel Vlodavsky, Eviatar Nevo